Dipeptidyl peptidase 4 (DPP-4) inhibitors is a new class of antihyperglycemic agents that is
now available for the treatment of type 2 diabetes. We investigated the relationship between …

We describe a 58-year-old man with a malignant melanoma metastasis to the liver. After
initiation of nivolumab therapy, he developed destructive thyroiditis and subsequently …

Methods This cross sectional study was conducted at the Joint Laboratory Office (JLO), Dokkyo
Medical University Koshigaya Hospital, Koshigaya, Japan from April 2010 to December …

An increase of serum ferritin, an indicator of body iron store, is associated with insulin
resistance and with an increased risk of type 2 diabetes in the general population. A low serum …

Canagliflozin has a robust inhibitory effect on sodium glucose transporter (SGLT)-2 and a
mild inhibitory effect on SGLT1. The main purpose of this study was to investigate the effect of …

Objective The main purpose of this study was to investigate the association of serum SerpinB1
levels and various parameters in patients with type 2 diabetes. The effect of canagliflozin (…

The main purpose of the current study was to investigate the effect of a combination of alogliptin
[a dipeptydil peptidase (DPP)-4 inhibitor] and lansoprazole [a proton pump inhibitor (PPI)…

Background The goal of the current study was to investigate the long-term effects (after 3
years or more) of alogliptin on glycemic control in Japanese patients with type 2 diabetes. …

Background Betatrophin is a hormone mainly secreted by the liver that influences lipid
metabolisms. The main purposes of this study were to investigate the effect of canagliflozin (a …

This study aims is to investigate the effect of medium-term insulin therapy (3 months) and
plasma glucose levels on corrected QT intervals (QTc) in patients with type 2 diabetes. The …